Mismatch Repair Deficiency (dMMR) Market Summary
Mismatch Repair Deficiency (dMMR) causes failure in DNA repair, leading to accumulation of mutations, including in oncogenes and tumor suppressor genes, which promotes uncontrolled cell proliferation and tumor development. dMMR/MSI-H therapies are currently approved for unresectable or metastatic colorectal cancer in adults and pediatric patients aged 12 years and older, as well as for recurrent or advanced endometrial cancer, while gastric cancer represents an emerging field where dMMR/MSI-H immunotherapy is under active clinical investigation. dMMR status is routinely determined for most solid tumors, as it predicts strong response to immunotherapy, with first-line recommendations from NCCN and ESMO for metastatic/unresectable or locally advanced colorectal, gastric, and other solid tumors.
Currently, FDA-approved therapies for dMMR include OPDIVO (Bristol Myers Squibb), KEYTRUDA (Merck), and JEMPERLI (GSK), while the pipeline remains robust with emerging therapies such as Zimberelimab + Domvanalimab (Arcus Biosciences/Gilead Sciences), HRO761 (Novartis), MDNA11 (Medicenna Therapeutics), and RO7589831 (Roche) currently in development to provide safe and effective treatment options.
DelveInsight’s “Mismatch Repair Deficiency (dMMR) Market Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth analysis of dMMR epidemiology, market, and clinical development, covering historical and forecasted epidemiology and market data along with a detailed analysis of dMMR market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report provides real-world prescription pattern analysis, emerging drugs assessment, market share, and uptake/adoption pattern of individual therapies, as well as historical and forecasted dMMR market size from 2020 to 2034 in the 7MM, along with current dMMR treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.
Explore DelveInsight’s Full Coverage on the Mismatch Repair Deficiency (dMMR) Market
Mismatch Repair Deficiency (dMMR) Overview and Diagnosis
dMMR refers to a defect in the cellular machinery responsible for correcting errors that arise during DNA replication. The normal mismatch repair (MMR) system identifies and repairs mismatches, incorrect base pairings, or small insertions/deletions that can occur during DNA synthesis or recombination. Loss of function in this pathway leads to the accumulation of DNA mutations, genomic instability, and an increased risk of cancer.
dMMR is diagnosed by testing tumor tissue for the loss of key mismatch repair proteins (MLH1, MSH2, MSH6, PMS2) using immunohistochemistry, or for microsatellite instability (MSI) using molecular assays. If dMMR is detected, further tests such as analysis for MLH1 promoter methylation or BRAF mutation help distinguish between inherited and sporadic causes. Germline genetic testing may be done to confirm hereditary conditions like Lynch syndrome. This stepwise approach allows precise identification of dMMR, guides cancer treatment, and helps inform family risk.
Mismatch Repair Deficiency (dMMR) Diagnosis and Treatment Algorithm
Treatment of dMMR tumors, often characterized by microsatellite instability-high (MSI-H) status, is centered on immune checkpoint inhibitors (ICIs), which have transformed outcomes due to the high immunogenicity of these cancers. Pembrolizumab is FDA-approved for any unresectable or metastatic MSI-H/dMMR solid tumor, while nivolumab (alone or with ipilimumab) and dostarlimab are approved for colorectal and endometrial cancers, respectively. Surgery remains key for localized disease, but ICIs are moving into earlier settings. Ongoing trials are exploring next-generation ICIs, combinations with CTLA-4 inhibitors, PARP inhibitors, vaccines, and cell therapies to expand benefit and overcome resistance.
Mismatch Repair Deficiency (dMMR) Market Players
Mismatch Repair Deficiency companies include:
- Bristol Myers Squibb
- Merck
- Arcus Biosciences/Gilead Sciences
- AstraZeneca
- Medicenna Therapeutics
- Roche
- Novartis
- And Others
Mismatch Repair Deficiency (dMMR) Epidemiology
As the market is derived using a patient-based model, the dMMR epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by indication-specific incident cases of mismatch repair deficiency, total incident cases of mismatch repair deficiency, stage-specific incident cases of mismatch repair deficiency, and total treatable cases of mismatch repair deficiency in the 7MM, covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.
Key Findings:
- In 2024, total incident cases of cervical cancer were nearly 40,100 in the 7MM
- In 2024, total incident cases of gastric cancer were nearly 44,700 in the 7MM
- In 2024, the highest number of incident cases of ovarian cancer was observed in the United States, with nearly 19,700 cases, followed by Japan, which accounted for nearly 12,700 cases
- Endometrial cancer has the highest dMMR rate, found in about 20–30% of cases, with some reports up to 40%
- Gastric cancer generally shows dMMR in 8–10% of cases
- Colorectal cancer shows dMMR in about 10–15% of cases, with variations depending on cohort and geography; some studies report up to 26% in certain settings, but 13–15% is typically most consistent for unselected CRC
- Among stage-specific HGSOC cases, advanced-stage (III–IV) disease had the highest contribution, at nearly 10,000 cases in 2024
Mismatch Repair Deficiency (dMMR) Market Outlook
dMMR/MSI-H cancers remain a high-value immuno-oncology segment driven by broad testing uptake and durable responses to PD-1 inhibitors. On the marketed side, KEYTRUDA (pembrolizumab, Merck) anchors the category with a tumor-agnostic US approval now fully converted, enabling use across unresectable/metastatic MSI-H/dMMR solid tumors. OPDIVO (nivolumab, BMS), including its nivolumab plus ipilimumab regimen, has expanded in dMMR/MSI-H metastatic colorectal cancer, further entrenching PD-1 leadership, while dostarlimab (GSK) and durvalumab (AstraZeneca) approvals in dMMR endometrial cancer are pushing checkpoint therapy earlier and into combinations, widening the addressable patient population. Looking ahead, competition intensifies from next-generation combinations like zimberelimab (anti-PD-1) plus domvanalimab (anti-TIGIT) and novel mechanisms such as HRO761 (Novartis), a first-in-class WRN helicase inhibitor biomarker-matched to MSI-H/dMMR biology. With MSI testing penetration rising and multiple first-line and peri-operative studies reading out, revenue should stay resilient despite PD-1 class crowding; differentiation will hinge on earlier-line use, combination efficacy, and biomarker-guided selection. Headwinds include pricing pressure/biosimilars in PD-1s and IP challenges around formulation life-cycle strategies, but overall the dMMR franchise is poised for continued growth and label breadth across tumor types.
Marketed Mismatch Repair Deficiency (dMMR) Drugs
- KEYTRUDA (pembrolizumab) – Merck
KEYTRUDA, developed by Merck, is a PD-1 immune checkpoint inhibitor that has become a cornerstone in modern oncology, approved across a wide range of cancers including melanoma, lung, head and neck, and MSI-H/dMMR solid tumors. It works by blocking the PD-1 pathway, restoring T-cell activity against cancer cells.
In May 2017, the FDA approved KEYTRUDA for adult and pediatric patients with unresectable or metastatic MSI-H or dMMR solid tumors.
- OPDIVO (nivolumab) – Bristol Myers Squibb
OPDIVO is a fully human IgG4 monoclonal antibody that targets the programmed death-1 (PD-1) receptor, restoring T-cell activity and enhancing anti-tumor immune responses. Developed by Bristol Myers Squibb, it is one of the most widely used immune checkpoint inhibitors and is approved for multiple cancers, including melanoma, non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, Hodgkin lymphoma, and gastrointestinal cancers. In the setting of dMMR or microsatellite instability-high colorectal cancer, nivolumab has demonstrated significant clinical benefit.
In April 2025, the US FDA approved OPDIVO (nivolumab) plus YERVOY (ipilimumab) as a treatment for patients with previously untreated MSI-H or dMMR unresectable or metastatic colorectal cancer.
Emerging Mismatch Repair Deficiency (dMMR) Drugs
The dMMR pipeline remains robust, with emerging therapies such as Zimberelimab + Domvanalimab, HRO761, MDNA11, and RO7589831 currently in development to expand treatment options across biomarker-defined solid tumors.
- Zimberelimab + Domvanalimab – Arcus Biosciences/Gilead Sciences
Zimberelimab is a PD-1 inhibitor and domvanalimab is a TIGIT inhibitor, both developed by Arcus Biosciences in collaboration with Gilead, and they are being studied in combination as a novel dual checkpoint blockade strategy. While zimberelimab restores T-cell activity by blocking PD-1 signaling, domvanalimab targets the TIGIT pathway. This dual immunotherapy strategy is also being explored in biomarker-driven cancers such as those with dMMR or MSI-H, and the combination is currently being evaluated in Phase II clinical trials for locally advanced gastric adenocarcinoma, MSI-H/dMMR gastric cancer, and MSI-H/dMMR gastroesophageal junction cancer.
In November 2024, Arcus Biosciences announced that domvanalimab plus zimberelimab improved overall survival in ARC-10, a randomized study in patients with PD-L1-high NSCLC.
- HRO761 – Novartis
HRO761 is a first-in-class WRN helicase inhibitor being developed by Novartis for the treatment of cancers with dMMR and MSI-H. dMMR/MSI-H tumors accumulate DNA errors and become highly dependent on the WRN helicase for survival, creating a synthetic lethality vulnerability. By selectively blocking WRN activity, HRO761 is designed to kill dMMR/MSI-H tumor cells while sparing normal tissue, offering a precision therapy approach beyond immunotherapy. HRO761 is currently in Phase I clinical development for the treatment of MSI-H or dMMR advanced unresectable or metastatic solid tumors, including colorectal cancer.
- MDNA11 – Medicenna Therapeutics
MDNA11 is an interleukin-2 replacement therapy currently in Phase I/II clinical development, delivered intravenously, for the treatment of MSI and/or dMMR advanced solid tumors.
- RO7589831 – Roche
RO7589831 is an oral WRN inhibitor currently in Phase I clinical development for advanced solid tumors harboring MSI and/or dMMR.
Download the Mismatch Repair Deficiency (dMMR) Market Report for In-Depth Insights on Pipeline and Forecast
Conclusion
The Mismatch Repair Deficiency (dMMR) market remains a high-value immuno-oncology segment, anchored by broad testing uptake and durable responses to PD-1 inhibitors such as KEYTRUDA and OPDIVO, which continue to expand across colorectal, endometrial, and other solid tumor indications. While checkpoint inhibitors remain the cornerstone of treatment, competition is intensifying from next-generation dual checkpoint combinations like zimberelimab plus domvanalimab and novel biomarker-matched mechanisms such as the WRN helicase inhibitors HRO761 and RO7589831. With MSI testing penetration rising and multiple first-line and peri-operative studies reading out, the dMMR franchise is expected to see continued revenue resilience despite pricing pressures and biosimilar competition in the PD-1 class. As differentiation increasingly hinges on earlier-line use, combination efficacy, and biomarker-guided selection, the dMMR market is poised for sustained growth and expanding label breadth across tumor types through 2034.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com
